These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


107 related items for PubMed ID: 10828061

  • 21. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Orend G, Hunter T, Ruoslahti E.
    Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
    [Abstract] [Full Text] [Related]

  • 22. Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase.
    Keenan SM, Bellone C, Baldassare JJ.
    J Biol Chem; 2001 Jun 22; 276(25):22404-9. PubMed ID: 11304535
    [Abstract] [Full Text] [Related]

  • 23. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1.
    Pagès P, Benali N, Saint-Laurent N, Estève JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L.
    J Biol Chem; 1999 May 21; 274(21):15186-93. PubMed ID: 10329727
    [Abstract] [Full Text] [Related]

  • 24. Checkpoints for vesicular traffic?
    Fiset A, Faure R.
    Biochem Cell Biol; 2001 May 21; 79(5):579-85. PubMed ID: 11716299
    [Abstract] [Full Text] [Related]

  • 25. Regulation of cdk2 activity in endothelial cells that are inhibited from growth by cell contact.
    Chen D, Walsh K, Wang J.
    Arterioscler Thromb Vasc Biol; 2000 Mar 21; 20(3):629-35. PubMed ID: 10712384
    [Abstract] [Full Text] [Related]

  • 26. Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells.
    Hu X, Zhang X, Zhong Q, Fisher AB, Bryington M, Zuckerman KS.
    Oncogene; 2001 Oct 18; 20(47):6840-50. PubMed ID: 11687963
    [Abstract] [Full Text] [Related]

  • 27. The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein.
    Geisen C, Moroy T.
    J Biol Chem; 2002 Oct 18; 277(42):39909-18. PubMed ID: 12149264
    [Abstract] [Full Text] [Related]

  • 28. Hyperoxia induces S-phase cell-cycle arrest and p21(Cip1/Waf1)-independent Cdk2 inhibition in human carcinoma T47D-H3 cells.
    Bilodeau JF, Faure R, Piedboeuf B, Mirault ME.
    Exp Cell Res; 2000 May 01; 256(2):347-57. PubMed ID: 10772807
    [Abstract] [Full Text] [Related]

  • 29. Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells.
    Cereseto A, Washington Parks R, Rivadeneira E, Franchini G.
    Oncogene; 1999 Apr 15; 18(15):2441-50. PubMed ID: 10229195
    [Abstract] [Full Text] [Related]

  • 30. Functional interaction between the bovine papillomavirus virus type 1 replicative helicase E1 and cyclin E-Cdk2.
    Cueille N, Nougarede R, Mechali F, Philippe M, Bonne-Andrea C.
    J Virol; 1998 Sep 15; 72(9):7255-62. PubMed ID: 9696820
    [Abstract] [Full Text] [Related]

  • 31. Pituitary adenylate cyclase activating polypeptide anti-mitogenic signaling in cerebral cortical progenitors is regulated by p57Kip2-dependent CDK2 activity.
    Carey RG, Li B, DiCicco-Bloom E.
    J Neurosci; 2002 Mar 01; 22(5):1583-91. PubMed ID: 11880488
    [Abstract] [Full Text] [Related]

  • 32. Phosphorylation of the myristoylated protein kinase C substrate MARCKS by the cyclin E-cyclin-dependent kinase 2 complex in vitro.
    Manenti S, Yamauchi E, Sorokine O, Knibiehler M, Van Dorsselaer A, Taniguchi H, Ducommun B, Darbon JM.
    Biochem J; 1999 Jun 15; 340 ( Pt 3)(Pt 3):775-82. PubMed ID: 10359664
    [Abstract] [Full Text] [Related]

  • 33. Cyclin A is present in the endocytic compartment of rat liver cells and increases during liver regeneration.
    Vergés M, Castro A, Jaumot M, Bachs O, Enrich C.
    Biochem Biophys Res Commun; 1997 Jan 03; 230(1):49-53. PubMed ID: 9020058
    [Abstract] [Full Text] [Related]

  • 34. Compartmentalization of the mitogen-activated protein kinase (MAPK) in hepatic endosomes: association with the internalized epidermal growth factor (EGF) receptor.
    Faure R, Gaulin JF, Bourgoin S, Fortier S.
    Mol Cell Biol Res Commun; 1999 May 03; 1(2):132-9. PubMed ID: 10356362
    [Abstract] [Full Text] [Related]

  • 35. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity.
    Hu W, Bellone CJ, Baldassare JJ.
    J Biol Chem; 1999 Feb 05; 274(6):3396-401. PubMed ID: 9920882
    [Abstract] [Full Text] [Related]

  • 36. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes.
    Nahum A, Hirsch K, Danilenko M, Watts CK, Prall OW, Levy J, Sharoni Y.
    Oncogene; 2001 Jun 07; 20(26):3428-36. PubMed ID: 11423993
    [Abstract] [Full Text] [Related]

  • 37. The p42/p44 mitogen-activated protein kinase activation triggers p27Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells.
    Delmas C, Manenti S, Boudjelal A, Peyssonnaux C, Eychène A, Darbon JM.
    J Biol Chem; 2001 Sep 14; 276(37):34958-65. PubMed ID: 11418594
    [Abstract] [Full Text] [Related]

  • 38. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1).
    Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ.
    J Clin Invest; 1999 Mar 14; 103(5):597-604. PubMed ID: 10074476
    [Abstract] [Full Text] [Related]

  • 39. Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells.
    Hsu SL, Hsu JW, Liu MC, Chen LY, Chang CD.
    Exp Cell Res; 2000 Aug 01; 258(2):322-31. PubMed ID: 10896783
    [Abstract] [Full Text] [Related]

  • 40. Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2.
    Lents NH, Keenan SM, Bellone C, Baldassare JJ.
    J Biol Chem; 2002 Dec 06; 277(49):47469-75. PubMed ID: 12359725
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 6.